发布求助
文献互助 智能选刊 最新文献

Neurodegenerative disease management最新文献

筛选
英文 中文
Interview with Nobutaka Hattori: a life researching Parkinson's disease pathogenesis. 专访服部信孝:研究帕金森病发病机制的一生。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2023-0010
Nobutaka Hattori
{"title":"Interview with Nobutaka Hattori: a life researching Parkinson's disease pathogenesis.","authors":"Nobutaka Hattori","doi":"10.2217/nmt-2023-0010","DOIUrl":"https://doi.org/10.2217/nmt-2023-0010","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"71-73"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9624822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parkinson's disease research in Morocco: a review. 摩洛哥帕金森病研究综述
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0021
Mohamed Daghi, Abdelhakim Lakhdar, Hicham El Otmani
{"title":"Parkinson's disease research in Morocco: a review.","authors":"Mohamed Daghi,&nbsp;Abdelhakim Lakhdar,&nbsp;Hicham El Otmani","doi":"10.2217/nmt-2022-0021","DOIUrl":"https://doi.org/10.2217/nmt-2022-0021","url":null,"abstract":"<p><p><b>Aim:</b> To quantify and provide an overview on the scientific productivity made by Moroccan academics in the research on Parkinson's disease (PD) and parkinsonism. <b>Materials & methods:</b> Scientific articles, in either English or French, were gathered from published literature in three recognized databases: PubMed, ScienceDirect and Scopus. <b>Results:</b> We identified 95 published papers from which 39 articles have been extracted after removing inadequate publications and duplications between databases. All articles were published between 2006 and 2021. The selected articles were subdivided into five categories. <b>Conclusion:</b> The Moroccan academia is presently facing a low productivity issues and a lack of research laboratories focusing on PD research. We anticipate that providing more budgetary funds will significantly improve the productivity of PD research.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"129-139"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of auditory cues on gait variability in people with Parkinson's disease and older adults: a systematic review. 听觉提示对帕金森病患者和老年人步态变异性的影响:一项系统综述。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2021-0050
Elinor C Harrison, Gammon M Earhart
{"title":"The effect of auditory cues on gait variability in people with Parkinson's disease and older adults: a systematic review.","authors":"Elinor C Harrison,&nbsp;Gammon M Earhart","doi":"10.2217/nmt-2021-0050","DOIUrl":"https://doi.org/10.2217/nmt-2021-0050","url":null,"abstract":"<p><p><b>Aim:</b> The goal of this study was to analyze the effects of external rhythmic auditory stimulation (RAS) on gait variability in older adults and people with Parkinson's disease (PD). <b>Methods:</b> Academic databases searched included PubMed, Web of Science, PEDro and Cochrane, from inception to September 2021. Eligible articles scored a minimum of 4 on the PEDro scale. <b>Results:</b> Twenty-three papers were included. People with PD show varied responses in gait variability to RAS during cued walking trials. Healthy older adults tended to increase variability during cued trials. Cue rates below preferred walking cadence tend to increase gait variability. <b>Conclusion:</b> Gait variability is closely associated with fall risk and an important consideration in development of gait rehabilitation techniques.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"113-128"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9925828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. 阿波啡舌下膜和左旋多巴对OFF发作患者的运动反应。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0038
Stuart H Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert, Fabrizio Stocchi
{"title":"Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.","authors":"Stuart H Isaacson,&nbsp;Alyssa Bowling,&nbsp;Ian Zhang,&nbsp;Eric Pappert,&nbsp;Fabrizio Stocchi","doi":"10.2217/nmt-2022-0038","DOIUrl":"https://doi.org/10.2217/nmt-2022-0038","url":null,"abstract":"<p><p><b>Aim:</b> Evaluate timing of motor improvement with carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO) in patients with Parkinson's disease and OFF episodes. <b>Methods:</b> A <i>post hoc</i> pooled analysis from two studies assessed Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) scores and investigator-rated FULL ON. <b>Results:</b> At 15 and 30 min following the prescribed first daily CD/LD dose, mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3, respectively, and FULL ON was achieved by 6.5 and 41.8% of patients. Following an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7 and 81.0% of patients. <b>Conclusion:</b> Concomitant administration of SL-APO with carbidopa/levodopa may be useful for delayed ON.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"75-84"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9623349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Updates and advances in multiple sclerosis neurotherapeutics. 多发性硬化症神经疗法的最新进展。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-02-01 Epub Date: 2022-10-31 DOI: 10.2217/nmt-2021-0058
Moein Amin, Carrie M Hersh
{"title":"Updates and advances in multiple sclerosis neurotherapeutics.","authors":"Moein Amin, Carrie M Hersh","doi":"10.2217/nmt-2021-0058","DOIUrl":"10.2217/nmt-2021-0058","url":null,"abstract":"<p><p>The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with novel mechanisms, provide more options for patients with MS. While treatment of MS neuroinflammation is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing research to develop agents for remyelination and neuroprotection. Further insights are needed to guide DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation in relapsing and progressive MS. This review provides a summary of these updates.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"47-70"},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. 专家意见对COVID-19疫苗和克拉德里滨片在MS：一个简单的语言总结。
IF 2.3
Neurodegenerative disease management Pub Date : 2023-02-01 Epub Date: 2022-10-24 DOI: 10.2217/nmt-2022-0027
Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout
{"title":"Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.","authors":"Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout","doi":"10.2217/nmt-2022-0027","DOIUrl":"10.2217/nmt-2022-0027","url":null,"abstract":"<p><strong>What is this summary about?: </strong>People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.</p><p><strong>What were the results?: </strong>The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.</p><p><strong>What do the results mean?: </strong>Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"5-13"},"PeriodicalIF":2.3,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies. 在接受natalizumab或其他疗法治疗的多发性硬化症患者中描述“感觉良好的体验”。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0003
John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila
{"title":"Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.","authors":"John Foley,&nbsp;Regina Berkovich,&nbsp;Mark Gudesblatt,&nbsp;Elizabeth Luce,&nbsp;Beth Schneider,&nbsp;Carl de Moor,&nbsp;Shirley Liao,&nbsp;Lily Lee,&nbsp;Karthik Bodhinathan,&nbsp;Robin Avila","doi":"10.2217/nmt-2022-0003","DOIUrl":"https://doi.org/10.2217/nmt-2022-0003","url":null,"abstract":"<p><p><b>Aim:</b> Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). <b>Methods:</b> Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. <b>Results:</b> The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. <b>Conclusion:</b> This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"23-34"},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10797634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. 用克拉德里滨片治疗多发性硬化症患者，对流感和水痘疫苗的影响的简单语言总结。
IF 2.3
Neurodegenerative disease management Pub Date : 2023-02-01 Epub Date: 2022-12-22 DOI: 10.2217/nmt-2022-0026
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert
{"title":"A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.","authors":"Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert","doi":"10.2217/nmt-2022-0026","DOIUrl":"10.2217/nmt-2022-0026","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of an article originally published in the <i>Multiple Sclerosis Journal</i>. Cladribine tablets (MAVENCLAD<sup>®</sup>) are an oral (taken by mouth) medication, approved for the treatment of people with relapsing forms of multiple sclerosis (MS, with episodes of new or worsening symptoms). They are administered for a maximum of 10 days per year, over a period of 2 years. Cladribine tablets work by temporarily reducing the number of lymphocytes, which are immune cells that help to fight off infections. Because of this, people with MS (also called PwMS) may have concerns about the effect of cladribine tablets on vaccines, as these work via immune cells to build protection against infection.</p><p><strong>What happened in the magnify-ms study?: </strong>A study called MAGNIFY-MS investigated how long it takes for cladribine tablets to begin to work in people with a type of MS called highly active relapsing MS. During the study, some participants received their usual vaccinations against flu (influenza) and against the chickenpox virus (also called varicella zoster virus) as part of their routine medical care. The MAGNIFY-MS study gave the researchers an opportunity to look at how cladribine tablets affect the way the flu and chickenpox virus vaccines work in the body.</p><p><strong>What were the results?: </strong>Cladribine tablets do not affect how well the body responds to flu and chickenpox vaccines.</p><p><strong>What do the results mean?: </strong>PwMS taking cladribine tablets who are vaccinated against chickenpox, flu or both can be protected against these diseases.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"15-21"},"PeriodicalIF":2.3,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9361631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Welcome to Volume 13 of Neurodegenerative Disease Management. 欢迎阅读《神经退行性疾病管理》第 13 卷。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0042
Emily Powell
{"title":"Welcome to Volume 13 of <i>Neurodegenerative Disease Management</i>.","authors":"Emily Powell","doi":"10.2217/nmt-2022-0042","DOIUrl":"10.2217/nmt-2022-0042","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9143453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension. 神经源性直立性低血压患者护理人员的健康相关生活质量和负担
IF 2.6
Neurodegenerative disease management Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0015
Katy Gallop, Ngan Pham, Grant Maclaine, Emma Saunders, Bonnie Black, Lena Hubig, Sarah Acaster
{"title":"Health-related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension.","authors":"Katy Gallop,&nbsp;Ngan Pham,&nbsp;Grant Maclaine,&nbsp;Emma Saunders,&nbsp;Bonnie Black,&nbsp;Lena Hubig,&nbsp;Sarah Acaster","doi":"10.2217/nmt-2022-0015","DOIUrl":"https://doi.org/10.2217/nmt-2022-0015","url":null,"abstract":"<p><p><b>Aim:</b> This study explores the burden of caring for an individual with neurogenic orthostatic hypotension (nOH) and an underlying neurodegenerative disease (Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies). <b>Materials & methods:</b> A survey including several validated instruments was conducted with informal caregivers of individuals with Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies. <b>Results:</b> Caregivers of patients with nOH (n = 60) reported greater burden across all outcomes compared with those without nOH (n = 60). Receiving pharmacological treatment for nOH was the variable most consistently associated with significantly better caregiver health-related quality-of-life (p < 0.05). <b>Conclusion:</b> This study demonstrates the burden of nOH on informal caregivers and highlights the potential benefit of pharmacological treatment not only for patients but also indirectly, their caregivers.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"35-45"},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10793820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信